CANSINOBIO (06185) News

Qiming Venture Partners Managing Partner Alex Zhou Named to 2026 Forbes Midas List

PR NewswireMay 29 15:21

HKEX Announcement Insights | Shougang Langze to launch IPO from May 26 to May 29, offering 40 million shares globally

Shougang Langze will offer shares from May 26 to May 29, proposing a global offering of 40 million shares; Hong Kong China Travel reported first-quarter revenue of HK$1.1 billion, an increase of 13% year-over-year.

Zhitong FinanceMay 26 08:57

CanSino Launches First-in-Class 24-Valent Pneumococcal Vaccine Trial

TipRanksMay 26 08:15

Company Q&A | CanSino: The company's recombinant Ebola virus vaccine is supplied only for emergency use and national stockpiling, with production arranged according to specific national requirements.

Gelonghui, May 21 — An investor asked CanSino Biologics on an interactive platform: 'An Ebola virus outbreak has occurred in the Democratic Republic of the Congo. Is your company’s Ebola vaccine effective against this strain? Does your company have the production capacity to supply the Ebola vaccine, and could the World Health Organization potentially procure your Ebola vaccine?' CanSino responded that its recombinant Ebola virus vaccine is intended solely for emergency use and national stockpiling, with production arranged according to specific national requirements. Additionally, the vaccine’s antigen is based on the 2014 Makona strain of Zaire ebolavirus, and further research is needed to evaluate its cross-protection efficacy against currently circulating strains. If the state

Gelonghui FinanceMay 21 17:03

CanSino Biologics Sets 2025 AGM With Broad Capital and Governance Mandates on Agenda

TipRanksMay 19 17:10

Company Q&A | CanSino: Currently advancing the research and development of mRNA vaccines for the treatment of glioblastoma, rhabdomyosarcoma, and other indications.

Gelonghui, May 14 | An investor asked CanSino on an interactive platform: "Has there been any progress on the cancer‑therapeutic vaccine mentioned in your previous announcement?" CanSino replied that, while continuing to strengthen its core business, the company is exploring product opportunities in the therapeutic space. It is currently advancing R&D on mRNA vaccines for indications such as glioblastoma and rhabdomyosarcoma, and will continue to build out its pipeline of candidate products. The company will also seize potential collaboration opportunities and explore various possibilities, taking into account the distinct characteristics of each product, the competitive landscape, and its future value prospects.

Gelonghui FinanceMay 14 15:34

Abnormal Fluctuation Statistics of Shanghai-Hong Kong Stock Connect | May 14

Intelligent Channel HK Stock Connect Ratio Anomaly Statistics | May 13, 2026

Zhitong FinanceMay 14 08:36

H-share Announcements | China Jinmao achieved a cumulative contracted sales amount of 31.234 billion yuan in the first four months, representing a year-on-year increase of 23.44%.

Tuya Inc reported a net profit of US$15.8 million in the first quarter, representing a year-on-year increase of 43.2%. Revenue from its AI business grew by 16.9%, emerging as a new growth driver. China Jinmao achieved cumulative contracted sales of RMB31.234 billion in the first four months, marking a year-on-year increase of 23.44%.

Zhitong FinanceMay 12 09:05

CanSino Biologics (06185.HK): The NDA for the Td5cp vaccine for adolescents and adults has been granted priority review by the Center for Drug Evaluation of the National Medical Products Administration.

CanSino Biologics (06185.HK) announced that the New Drug Application (NDA) for its adsorbed acellular pertussis (five-component) diphtheria and tetanus combined vaccine (for use in individuals aged 6 years and above) ("Td5cp for adolescents and adults") has been granted priority review status by the Center for Drug Evaluation of the China National Medical Products Administration. According to the regulations governing priority review and approval, the Center will allocate resources preferentially to evaluate NDAs included in this process. Td5cp for adolescents and adults is suitable for individuals aged 6 years and above and serves as a booster vaccine against diphtheria, tetanus, and pertussis for adolescents and adults.

Gelonghui FinanceMay 11 16:48

Express News | 14:00 Quick Commentary: Significant divergence between the Huangbai lines, with localized strength in short-term sentiment.

BreakingsMay 11 14:07

A-share market movement | The Hantavirus outbreak draws attention! The virus prevention and treatment sector collectively surged, with Wantai Biotech up 9% and BGI Genomics rising over 5%.

Gelonghui, May 11 | Virus prevention and control concept stocks collectively rose in the A-share market. Among them, Walvax Biotech surged 19%, Capricorn Bio-Tech increased by over 15%, Daan Gene hit a 10% price limit, Wantai BioPharm gained 9%, Kangtai Biological Products rose over 8%, Zhifei Biological Products climbed 7%, and Frontier Biopharma-U, Probiotics Pharmaceuticals, CanSino Biologics, Wondfo Biotech, and Kanghua Biological Products increased by over 6%. Additionally, Jindike Biologics, BGI Group, Sichuan Maik Biotechnology, and TopRim Pharmaceuticals saw gains exceeding 5%. In terms of news, the cruise ship 'Hondeus' recently reported an outbreak of Hantavirus. Furthermore, a fatal case of Hantavirus was reported in Taipei City, Taiwan, related to infections carried by rats, drawing significant public attention.

Gelonghui FinanceMay 11 13:35

As the ASCO annual meeting approaches, the number of LBA for domestically innovative drugs has reached a new high, with three key investment themes worth noting.

A total of 63 studies were selected as Late-Breaking Abstracts (LBA) at this year's ASCO, including 13 studies from 12 companies based in China; notable domestically developed innovative drugs selected for LBA include AK112 from Akeso Biopharma and sintilimab plus chemotherapy from Innovent Bio; Huatai Securities stated that China's innovative drug sector is rapidly emerging as a defining force in global oncology treatment paradigms, with first-line lung cancer being one of the key focuses at this year’s ASCO.

cls.cnMay 4 14:15

CanSino Biologics (06185.HK) will release its financial report on April 28.

CanSino Biologics (06185.HK) will release its financial report on April 28. Investors are advised to stay tuned. What about the previous performance? In Q1 2025, the company reported operating revenue of 137 million yuan, a net profit of -11.5454 million yuan, and earnings per share of -0.05 yuan. Niuniu Reminder: 1. There are no rigid regulations on the division of accounting years for Hong Kong-listed and US-listed companies, which is entirely determined by the enterprises themselves. Therefore, each financial reporting period can serve as the company’s annual report cutoff date without being tied to the calendar year as the fiscal year. 2. Generally speaking, the company will hold an earnings call on or around the aforementioned financial report release date.

Futu NewsApr 30 02:45

Stock Movement | CanSino Biologics (06185) Plummets Over 6% Intraday; Q1 Revenue Increases Nearly 40% Year-on-Year, Net Loss Widens 2.5-Fold

CanSino Biologics (06185) fell more than 6% during trading, and as of press time, it had dropped by 4.81%, trading at HKD 30.5 with a turnover of HKD 46.4069 million.

Zhitong FinanceApr 29 11:42

CanSino: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

CanSino's Q1 revenue increased by nearly 40% due to expense provisions, leading to an expanded loss. Dependence on core products remains unresolved.

① Overall, CanSino's operations have shown signs of improvement, with a net profit attributable to shareholders of 27.8727 million yuan in 2025, achieving a turnaround from losses to profits; ② The company's core revenue still heavily relies on a single product category (meningitis), and non-recurring adjustments failed to achieve profitability. Continued attention should be paid to the scaling speed of new products and the realization of international orders.

cls.cnApr 28 21:24

CanSino Biologics Tightens Governance With Proposed Articles and Board Rule Changes

TipRanksApr 28 17:15

CANSINOBIO: FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026

HKEXApr 28 16:56 · Announcements

CANSINOBIO: 2025 ANNUAL REPORT

HKEXApr 22 16:43 · Announcements